Mouse-study observations In the Billon 2023 and Billon 2024 studies, mice dosed at 25-50 mg/kg IP for up to 28 days showed no overt toxicity, no sickness-related weight loss, no liver-enzyme signal at the doses tested, and no cardiac dysfunction
H&E staining and immunostaining for CD45 did not reveal any differences between OTA-treated and control mice 24 h after administration, nor did the combination of OTA and ABT lead to any obvious histological changes (Fig
Src kinase activation by nitric oxide promotes resistance to anoikis in tumour cell lines
Cardiometabolic Benefits: Beyond its impact on weight and blood sugar, semaglutide may offer additional cardiometabolic benefits
Not intended for use by pregnant or breastfeeding women
In bipolar disorder, an increase in cortisol secretion may be seen in the manic phase (259)